Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatoh...
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH
About this item
Full title
Author / Creator
Publisher
Japan: Japan : Springer Japan
Journal title
Language
English
Formats
Publication information
Publisher
Japan: Japan : Springer Japan
Subjects
More information
Scope and Contents
Contents
Background Advanced glycation endproducts (AGEs), final reaction products of protein with sugars, are known to contribute to various disorders, including diabetes, aspects of aging, and neurodegenerative diseases. Recently, we reported elevated levels of serum AGEs in patients with nonalcoholic steatohepatitis (NASH); further, we found that AGEs in...
Alternative Titles
Full title
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_746310234
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_746310234
Other Identifiers
ISSN
0944-1174
E-ISSN
1435-5922
DOI
10.1007/s00535-010-0203-y
